Is it still possible to ameliorate the diagnosis of refractory anemia?

Leukemia Research

Volumn 27, Issue 3, 2003, Pages 201-203

  Goasguen, Jean E ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; BLAST CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL FEATURE; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; ERYTHROCYTE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MONOCYTE; MORBIDITY; MYELODYSPLASTIC SYNDROME; NOTE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; SURVIVAL RATE; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

ANEMIA, REFRACTORY; CHROMOSOMES, HUMAN, PAIR 5; CLASSIFICATION; CYTOGENETIC ANALYSIS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0037354737     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00174-1     Document Type: Note

References (14)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R.et al. The French-American-British (FAB) co-operative group. Proposals for the classification of the myelodyplastic syndromes. Br. J. Heamatol. 51:1982;189-199.
2. Gatterman N., Aul C., Schneider W. Two types of acquired idiopathic sideroblastic anemia (AISA). Br. J. Haematol. 74:1990;45-52.
3. Garand R., Gardais J., Bizet M., Bremond J.L., Accar F., Goasguen J.E. Heterogeneity of acquired idiopathic sideroblastic anemia (AISA). Leuk. Res. 16:1992;463-468.
4. Tefferi A., Hoagland H.C., Therneau T.M., Pierre R.V. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin. Proc. 10:1989;1246-1254.
5. Brito-Babapulle F., Catovsky D., Galton D.A.G. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodyplasia. Br. J. Haematol. 66:1987;445-454.
6. Goasguen J.E., Matsuo T., Cox C., Bennett J.M. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukaemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 6:1992;520-525.
7. Rosati S., Mick R., Xu F., Stonys E., LeBeau M.M., Larson R.et al. Refractory cytopenia with multilineage dysplasia: further characterization of an unclassifiable myélodyplastic syndrome. Leukemia. 10:1996;20-26.
8. Sanz G.F., Sanz M.A., Vallespi T., Canizo M.C., Torrabadella M., Garcia S.et al. Twa regression models and a scoring system for predicting survival and planning treatment in myelodyplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395-408.
9. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E.et al. Cytogenetic analysis has a strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leikemia. 7:1993;1315.
10. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G.et al. International scoring system for evaluating prognosis anemia. Leukemia. 89:1998;2079-2088.
11. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tomours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
12. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24:2000;983-992.
13. Cermak J, Michalova K, Brezinova J, Zemanova Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 2003;27:221-29.
14. Nösslinger T., Reisner R., Koller E., Grüner H., Tchler H., Nowotny H.et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 98:2001;2935.